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APP ȕ-amyloid precursor protein
BACE1 ȕ-secretase 
CHO Chinese hamster ovary
HCD Higher energy collisional dissociation
HILIC Hydrophilic interaction liquid chromatography
EEA1 Early Endosome Antigen 1 - early endosomal marker
ESI Electrospray ionization
FASP Filter aided sample preparation
GO Gene ontology
LAMP1 Lysosomal Associated Membrane Protein 1 - lysosomal marker
LSD Lysosomal storage disorder
MALDI Matrix-assisted laser desorption/ionization
MS Mass spectrometry
NAG N-Acetyl-ȕ-D-glucosaminidase
NPC Niemann-Pick Type C
PD Parkinson’s disease
Rab7 RAS-related GTP-binding protein 7- late endosomal marker
SPE Solid-phase extraction
TfR Transferrin receptor – a marker of recycling endosomes
TOF Time-of-flight
UPLC Ultra-performance liquid chromatography
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Summary
Increasing evidence implicates lysosomal dysfunction in the pathogenesis of neurodegenerative 
diseases, including the rare inherited lysosomal storage disorders (LSDs) and the most common 
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease (AD and PD). While 
the triggers of the lysosomal impairment may involve the accumulated macromolecules or 
dysfunction of the lysosomal enzymes, the role of the lysosomal glycocalyx in the lysosomal 
(dys)function has not been studied. The goal of this work was to analyze whether there are 
changes in the lysosomal glycocalyx in a cellular model of a LSD Niemann-Pick type C disease 
(NPC). Using the ferrofluid nanoparticles we isolated lysosomal organelles from NPC1-null and 
CHOwt cells. The magnetically isolated lysosomal fractions were enriched with the lysosomal 
marker protein LAMP1 and showed the key features of NPC disease: 3-fold higher cholesterol 
content and 4-5 fold enlarged size of the particles compared to the lysosomal fractions of wt 
cells. These lysosomal fractions were further processed to isolate lysosomal membrane proteins 
using Triton X-114 and their N-glycome was analyzed by HILIC-UPLC. N-glycans presented in 
each chromatographic peak were elucidated using MALDI-TOF/TOF-MS. We detected changes 
in the N-glycosylation pattern of the lysosomal glycocalyx of NPC1-null vs. wt cells which 
involved high-mannose and sialylated N-glycans. To the best of our knowledge this study is the 
first to report N-glycome profiling of the lysosomal glycocalyx in NPC disease cellular model 
and the first to report the specific changes in the lysosomal glycocalyx in NPC1-null cells. We
speculate that changes in the lysosomal glycocalyx may contribute to lysosomal (dys)function. 
Further glycome profiling of the lysosomal glycocalyx in other LSDs as well as the most 
common neurodegenerative diseases, such as AD and PD, is necessary to better understand the 
role of the lysosomal glycocalyx and to reveal its potential contribution in lysosomal dysfunction 
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leading to neurodegeneration. 
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Introduction
Since their first description scientists have tried to fully characterize lysosomal composition and 
function. Today, many facts are known about lysosomal physiology. The acidic pH, ionic 
gradients and the membrane potential make lysosomes an ideal environment for activity of 
luminal lysosomal hydrolases and a cellular center for nutrient sensing and recycling (1).
Lysosome’s primary role is to digest a cargo from endocytic, phagocytic or autophagocytic 
pathways. More than 50 lysosomal hydrolases have been characterized and dysfunction in their 
activity/levels leads to accumulation of the lysosomal cargo which causes lysosomal storage 
disorders (LSDs) (2). Besides luminal hydrolases, integral lysosomal membrane proteins are also 
important for proper function of lysosomes. Mutations in genes encoding these proteins lead to 
defects in the transport of lysosomal cargo and/or ions across the lysosomal membrane also 
causing the LSDs (3). Individuals with lysosomal storage disorders often develop symptoms 
early in life and in majority of LSDs the brain, especially neurons, are affected (4).
Niemann-Pick Type C (NPC) disease is a rare, autosomal recessive, progressive and fatal 
disorder characterized by abnormal cholesterol trafficking and intracellular accumulation of 
cholesterol and glycosphingolipids in late endosomes and lysosomes. NPC is caused by loss of 
function of either NPC1, a multi-transmembrane lysosomal protein, or NPC2, a small luminal 
lysosomal protein that mediate intracellular cholesterol transport (5). Recently, NPC disease has 
shown to share several pathological features with the most common and complex Alzheimer’s 
disease (AD) (6). Our previous work has suggested that dysfunction of the late 
endosomal/lysosomal compartments in NPC1-cellular model is, most likely, responsible for the 
AD-like features in NPC (7, 8), and that increased levels of free cholesterol in NPC play an 
important role in compartmentalization of the key AD-proteins (ȕ-amyloid precursor protein -
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APP and ȕ-secretase - BACE1) within lipid rafts (9) or in modulation of membrane stiffness
lading to sequestration of both APP and BACE1 within the endolysosomal pathway (10).
Besides cholesterol, other lipids, especially phospholipids and sphingolipids are also involved in
these processes (11).
Glycosylation is one of the most common co-translational and post-translational modification 
which regulates the structure, stability, localization and function of various proteins, and N-
glycosylation has been the most studied type of it (12). N-glycans are known to be versatile and 
responsive to environmental stimuli, and undergo significant changes in numerous diseases 
including those of central nervous system (13–17). Moreover, it has been recently shown that 
modulation of glycosylation of APP, a key protein in the pathogenesis of AD, may represent a 
potential target for AD therapy (18). It has been previously shown that glycoproteins accumulate 
in NPC model (19), and that blocking the O-linked glycosylation lowers cholesterol levels and 
increases the number of lysosomes (20), thus rescuing the NPC cellular defects. In the present 
work, we studied N-glycosylation profile of the lysosomal membrane proteins in NPC1-null cells
vs. wt-cells. We tested the hypothesis that alteration of the lysosomal glycocalyx is an additional 
feature of the lysosomal dysfunction in NPC disease, as well as in other LSDs. 
To the best of our knowledge, here we describe the first complete N-glycome of the lysosomal 
glycocalyx in NPC disease cellular model, which potentially could be useful for restoring
lysosomal storage defects in NPC disease and other LSDs as well as for rescuing pathological 




Chinese hamster ovary wild type cells (CHOwt), CHO cells lacking NPC1 protein (NPC1-null) 
and NPC1-null cells stably express human NPC1 protein (NPC1-null + NPC1) were kindly 
provided by Dr. Daniel Ory. The cells were grown in DMEM/F12 medium supplemented with 
10% FBS, 2 mM L-glutamine and antibiotic/antimycotic mix, all from Sigma-Aldrich.
Magnetic separation of lysosomes form whole cells
Lysosomes were purified according the Walker and Lloyde Evans protocol (21). Briefly, the 
cells were grown in T75 flasks, they were incubated with 10% ferrofluid solution 
(superparamagnetic iron oxide nanoparticles, 10 mg/mL of 40 kDa dextran-stabilized magnetite, 
Liquids Research Ltd, UK.) and 10 mM HEPES pH 7.2 in growth medium for 24 hours. After 
washing and the chase period in the regular medium for 24 hours, cells were trypsinized, 
harvested and resuspended in 2 mL of hypotonic buffer (15 mM KCL, 1.5 mM MgAc, 1 mM 
DTT, 10 mM HEPES and proteinase inhibitor (Roche)). After homogenization in dounce 
homogenizer (30 times) and passing through 23G needle (10 times), 0.5 mL of hypertonic buffer 
was added (220 mM HEPES pH 7.2, 0.1 mM sucrose, 375 mM KCl, 22.5 mM MgAc, 1 mM 
DTT, 50 mL of DNase 1 (Roche Applied Science)). Following incubation for 5 min, the cellular 
homogenate was centrifuged and the same amount of proteins in the supernatant of CHOwt and 
NPC1-null cells was subjected to MS column (MACS Miltenyi Biotec) activated with 0.5% BSA 
in PBS and attached to QuadroMACS magnetic separator. Flow-through was collected, and 
column was washed with DNAse solution and Phosphate Buffer Saline (PBS) supplemented with 
0.1 mM sucrose. The column was removed from magnetic separator and lysosomes were eluted 
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with 0.5 mL of PBS supplemented with 0.1 mM sucrose and proteinase inhibitor cocktail (Roche 
Applied Science). All collected fractions were stored at -80 °C prior analysis.      
Western blot
Isolated fractions were mixed with sample buffer (6 times concentrated: 60% glycerol, 12% 
SDS, 3% DTT, 1/8 v/v 0.5 M Tris pH 6.8, bromphenol blue) and ȝ/RIHDFKIUDFWLRQ
including the cell lysate (the input) was subjected to SDS–PAGE on 8% Tris-glycine gel. 
Proteins were transferred to PVDF membrane (Roche Applied Science), and blocked with I-
block (Tropix). LAMP1 (rabbit polyclonal, Sigma-Aldrich) was used as a lysosomal marker and 
EEA1 (mouse monoclonal, BD Transduction Laboratories) was used as an early endosomal 
marker. Actin (rabbit polyclonal, Sigma-Aldrich) was used as a loading control. For detection, 
HRP conjugated secondary antibodies mouse/rabbit (Bio-Rad) were used. Proteins were 
visualized by chemiluminescence using POD chemiluminescence blotting substrate (Roche 
Applied Science) on UviTec (UVItec ltd. Cambridge). Western blots were quantified using 
ImageJ software (National Institutes of Health). Statistical validation of the data was achieved by 
Student t-test.
Protein and cholesterol levels
Total protein concentration was measured using commercially available Pierce BCA Protein 
Assay Kit (Thermo Scientific) according to manufacturer's protocol on Multiskan EX (Thermo 
Scientific). Total cholesterol concentration was measured using commercially available 
AmplexRed Cholesterol Assay (Molecular Probes) according to manufacturer's protocol on 
Fluoroskan Ascent FL (Thermo Scientific).
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Enzymatic activity measurement
N-Acetyl-ȕ-D-glucosaminidase (NAG) activity was measured using 4-Nitrophenyl N-acetyl-ȕ-
D-glucosaminide substrate (Alfa Aesar). Ten μL of lysate fraction and lysosomal fraction were 
mixed with 90 μL of substrate (1 mg/mL in 0.09 M Citrate buffer solution, pH 4.8). After 30 
minutes of incubation at 37 °C the reaction was stopped my adding 200 μL of 0.4 M Na2CO3. 
The absorbance of p-nitrophenylate ion was measured at 405 nm.
Particle size measurement
The hydrodynamic size of isolated lysosomes was measured using a Zetasizer Nano ZS 
instrument (Malvern). The hydrodynamic size was measured from a dilute (1:20) suspension of 
the sample in PBS pH 7.4 in a disposable plastic cuvette at 25 °C. The results were analyzed 
using the Zetasizer software v.6.32 provided by the manufacturer.
Dextran uptake assay
Cells were grown on 12 mm glass covered slips and treated with 40 kDa dextran labeled with 
Fluorescein (Molecular Probes, Invitrogen) in growth medium for 24 hours. Cells were washed 
with PBS and further grown in the fresh growth medium for additional 0, 2, 4, 6, 8 and 24 hours. 
After that cells were washed again in PBS and fixed in 4% paraformaldehyde (Sigma-Aldrich) 
and mounted with Polyvinyl alcohol mounting medium with DABCO antifading (Fluka). All 
samples were analyzed using inverted fluorescent confocal microscope Leica SP8 X FLIM.
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For measuring cellular and secreted fluorescein labeled dextran, cells were grown in 6 well 
plates, they were incubated with 40 kDa fluorescein-labeled dextran for 24 hours, following 
washing and 24 hours chase in the regular medium. As a control the cells which were not 
incubated with dextran were used. Cells were lysed (50 mM Tris pH 7.6, 150 mM NaCl, 2mM 
EDTA, 1% NP40, proteinase inhibitor) and fluorescein levels in the cell lysate and in the 
medium were measured on Fluoroskan Ascent FL (Thermo Scientific). 
Mass spectrometric proteomics analysis
Lysosomal fractions were prepared in triplicate and processed using filter aided sample 
preparation (FASP) protocol (22) with some modifications. For the analysis, 8 ȝJRIWRWDOSURWHLQ
from lysosomal fraction were mixed with the FASP-urea buffer (8 M urea in 0.1 M Tris–HCl 
pH 8.5) to final volume of 150 μL. SDS (Sigma-Aldrich) was added to final concentration of 1% 
(v/v). Before FASP, samples were sonicated for 10 minutes using ultrasonic bath, reduced (10 
mM DTT, 30 min, 55 °C) and mixed with 100 μL of FASP-urea buffer. After transferring to the 
10-kDa membrane filter units (Microcon YM-10, Merck Millipore), samples were centrifuged 
(13 000 x g, 45 min, 22 °C) and washed subsequently with 200 μL of FASP-urea buffer followed 
by centrifugation. Before digestion, proteins were alkylated (50 mM IAA, 20 min at room 
temperature in the dark), washed twice with FASP-urea buffer and then twice with ammonium 
bicarbonate (50 mM NH4HCO3 pH 7.6) followed by centrifugation (13 000 x g, 30 min). Protein 
digestion was achieved by adding trypsin (Promega) (enzyme-to-protein ratio 1:30, v/v) and by 
incubation at 37 °C overnight. Tryptic peptides were collected from filter units by centrifugation 
(13 000 x g, 30 min), washing with 50 μL of ammonium bicarbonate (50 mM NH4HCO3 pH 
7.6) and subsequent centrifugation, followed by vacuum drying. 
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Peptides were dissolved in loading solvent (1% ACN, 0.1% formic acid) and separated using 
Ultimate 3000 RSLCnano system (Dionex) before on-line ESI-MS/MS analysis by Q Exactive 
Plus mass spectrometer (Thermo Fisher Scientific). A total of amount of 1.5 μg was injected 
onto the trapping column (C18 PepMap100, 5 μm, 100A, 300 μm x 5 mm). After washing for 15 
min with loading solvent at a flow rate of 15 μL/min, peptides were eluted onto the analytical 
column (PepMaS56/&&FP[ȝP) using linear gradient 5-45% mobile phase B 
(0.1% formic acid in 80% ACN) over 150 min, 45% to 90% for 2 min, held at 80% for 2 min and 
re-equilibrated at 5% B for 20 min at a flow rate of 300 nL/min. Mobile phase A consisted of 
0.1% formic acid in water. Eluate from the column was introduced into the mass spectrometer 
via Nanospray Flex ion source and SilicaTip emitter (New Objective). The ionization voltage 
was set at 1.9 kV and the ion transfer capillary temperature at 250 °C. MS was operating in 
positive ion mode using HCD MS2 in data dependent acquisition mode. Full scan FTMS spectra 
were acquired in range from m/z 350.0 to 1800.0 with a resolution of 70000. The maximum 
injection time for FTMS full scan was set at 100 ms reaching an automatic gain control (AGC) 
target value of 1x106. Top 15 most intense precursor ions were chosen for further HCD 
fragmentation with a resolution of 17500 using injection time 60 ms and MS2 AGC target of 
1x105. The collision energy was set as 28% NCE. A ± 1.7 Da isolation window was applied to 
isolate precursor ions with dynamic exclusion of 15 s. MS raw files were processed by Proteome 
Discoverer software (version 2.0.0.802., Thermo Fisher Scientific) and SEQUEST search against 
Homo sapiens FASTA files (42116 sequences, downloaded 2016-05-11 from SwissProt 
database, TaxID=9609 and subtaxonomies). Static peptide modification included 
carbamidomethylation (C), and dynamic oxidation (M) and deamidation (N,Q). Maximum two 
trypsin missed cleavage sites were allowed. Precursor tolerance and ion fragment tolerance were 
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set at 10 ppm and 0.05 Da, respectively. Percolator confidence levels were set at 1% false 
discovery rate (FDR) (high) and 5% FDR (middle), for both peptide and protein levels FDR is 
determined automatically by Percolator node based on targeted-decoy strategy (23). For peptide 
confidence, validation was based on q-value (minimal FDR at which the identification is 
considered correct (24)) which was set at 0.01 (high). At least two unique peptides and 5% FDR 
were required for reporting confidently identified proteins. 
Gene ontology analysis of identified proteins was performed using Database 
for Annotation, Visualization and Integrated Discovery (DAVID) (version 6.8) (25). The 
significance of enrichment (p-value) and enrichment rate (fold enrichment) was calculated by 
DAVID tool.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (26) partner repository with the dataset identifier PXD008438.
Membrane protein isolation using Triton-X114, protein extraction, glycan release and fluorescent 
labeling 
The whole procedure was performed as previously reported (27). Briefly, the most hydrophilic 
molecules from commercial Triton X-114 were eliminated by adding of 490 mL of 10 mM Tris-
HCl pH 7.4, 150 mM NaCl and keeping the solution at 4 °C for Triton X-114 dissolution and at 
37 °C for its condensation. The whole procedure was repeated three times. Isolated lysosomes 
were homogenized in Triton lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% (v/v) Triton X-114 in PBS and protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
Germany)), using an ultrasonic processor (UP100H Hielscher, Teltow, Germany)(four cycles, 
15-20 s). Samples were then incubated overnight at 4 °C and the lysosome lysate was clarified 
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by centrifugation (30 min, 10 000 x g, 4 °C). The clear supernatant was overlaid on 200 μL of 
sucrose cushion (6% (w/v) sucrose, 10 mM Tris-HCl pH 7.4, 150 mM NaCl and 0.06% Triton 
X-114) and incubated at 37 °C for 20 min. Clouding of the solution occurred. Samples were 
centrifuged for 3 min, 400 x g, 37 °C and two phases (detergent-rich and detergent-poor) formed. 
The detergent-poor phase was transferred to a fresh tube and kept on ice. The detergent-rich
phase was resuspended in 500 μL of cold PBS and the phase separation was repeated. This 
aqueous phase was pooled with initial one and re-extracted by adding 50 μL of Triton stock 
solution and the phase separation was performed as described previously. 
Proteins from each phase were isolated by adding four times the sample volume of methanol and 
twice the initial sample volume of chloroform (Merck, Darmstadt, Germany) and vortexed well. 
At the end, three times of the initial sample volume of water was added, samples were vortexed 
vigorously and centrifuged for 1 min, 9 000 x g, 4 °C. After centrifugation the proteins were 
located in the liquid interphase. The aqueous top layer was removed, an additional three volumes 
of methanol were added after which the samples were vortexed and centrifuged again for 2 min, 
9 000 x g, 4 °C to pellet the proteins. Supernatant was removed, as much as possible without 
disturbing the precipitate, and samples were left to air-dry. 
The isolated proteins were denatured with the addition of SDS (Invitrogen, USA) and by 
incubation at 65 °C. The excess of SDS was neutralized with Igepal-CA630 (Sigma-Aldrich, 
USA) and N-glycans were released following the addition of PNGase F (Promega, USA) in PBS. 
The released N-glycans were labeled with 2-AB. Free label and reducing agent were removed 
from the samples using hydrophilic interaction liquid chromatography solid-phase extraction 
(HILIC-SPE). Glycans were eluted with ultrapure water and stored at –20 °C until use.
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The cell lysate proteins were prepared using the same protocol except there was not membrane 
protein isolation. 
Ultra-performance liquid chromatography (UPLC)
Fluorescently labeled N-glycans were separated by HILIC on an Acquity UPLC instrument 
(Waters, USA) consisting of a quaternary solvent manager, sample manager, and an FLR 
fluorescence detector set with excitation and emission wavelengths of 250 and 428 nm, 
respectively. The instrument was under the control of Empower 3 software, build 3471 (Waters). 
Labeled N-glycans were separated on a Waters BEH Glycan chromatography column, 150 × 2.1 
mm i.d., 1.7 μm BEH particles, with 100 mM ammonium formate, pH 4.4, as solvent A and 
ACN as solvent B. The separation method used a linear gradient of 30-47% solvent A at flow 
rate of 0.56 mL/min in a 23 min analytical run. Samples were maintained at 10 °C before 
injection, and the separation temperature was 25 °C. Data processing was performed using an 
automatic processing method with a traditional integration algorithm, after which each 
chromatogram was manually corrected to maintain the same intervals of integration for all the 
samples. The chromatograms were all separated in the same manner into 37 and 25 
chromatography peaks for the lysosomal and cell lysate N-glycome, respectively. HILIC-UPLC 
chromatograms were used for quantification, and abundance of each glycan was expressed as 
percentage of total integrated area.  
Glycan ethyl esterification and determined by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI- TOF/TOF -MS) analysis
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The identity of N-glycans separated by HILIC-UPLC was determined by MALDI-TOF/TOF-
MS. Prior to MS analysis, fractions of each N-glycan chromatography peak were collected, dried 
down in a vacuum concentrator and resuspendeGLQȝ/RIXOWUDSXUHZDWHU. To stabilize and 
GLVWLQJXLVKĮ-OLQNHGIURPĮ-linked sialic acids ethyl esterification was performed as 
previously described (28)$OLTXRWVRIȝ/ZHUHVSRWWHGRQWRD073$QFKRU&KLS%&
MALDI target (Bruker Daltronics, Bremen, Germany), mixed on plate with 1 μL of matrix 
solution (5 mg/mL 2,5-DHB, 1 mM NaOH in 50% acetonitrile) and left to dry by air. 
Recrystallization was performed by adding 0.2 μL of ethanol to each spot. Analyses were 
performed in positive-ion reflectron mode on an UltrafleXtreme MALDI-TOF/TOF-MS 
equipped with a Smartbeam-II laser and FlexControl 3.4 software Build 119 (Bruker Daltonics). 
The instrument was calibrated using a plasma N-glycome standard. A 25 kV acceleration voltage 
was applied after a 140 ns extraction delay. A mass window of m/z 1 000 to 5 000 with 
suppression up to m/z 900 was used for N-glycan samples. For each spectrum, 10 000 laser shots 
were accumulated at a laser frequency of 2 000 Hz, using a complete sample random walk with 
200 shots per raster spot. N-glycan structures were assigned using GlycoMod (29)
(http://web.expasy.org/glycomod/) for finding oligosaccharide composition from obtained mass 
using following settings: entering monoisotopic mass which in case of sialic acid was subtracted 
for 28 Da for each ester and increased for 18 Da for each lacton, mass tolerance of 0.5 Da and 
mass of 143 Da which included mass of 2-AB and Na+ as an adduct. NIBRT Glycobase (30)
(http://glycobase.nibrt.ie/glycobase/browse_glycans.action ) was used to confirm that a
suggested N-glycan elutes in a distinct chromatographic peak using glucose units as well as 
knowledge of the biosynthetic pathway of N-glycans with an emphasis on specificity of N-
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glycosylation  in CHO cell line (31, 32). Finding of informative fragments after MS/MS analysis 
to confirm a structure was performed using GlycoWorkbench (33).
Statistical analysis 
In order to remove experimental variation from measurements, normalization was performed on 
UPLC glycan data. To make measurements across samples comparable, normalization by total 
area was performed in which the area of each glycan peak was divided by the total area of the 
corresponding chromatogram. Differences in lysosomal (and whole-cell-lysate) N-glycomes 
between NPC1-null and CHOwt cells were determined using a general linear model. Prior to the 
analyses, normalized glycan measurements were log-transformed due to right skewness of their 
distributions. False discovery rate was controlled using Benjamini– Hochberg procedure. Data 




Lysosomal isolation from NPC1-null and CHOwt cells using the magnetic beads
Traditionally, lysosomes have been isolated using different gradient centrifugation techniques. In 
this work we adopted recently published method for lysosomal isolation using ferrofluid particles
(21). Using this method we isolated lysosomal fractions which were positive for LAMP1 
(lysosomal marker) and negative for EEA1 (early endosome marker) (Figure 1A). It should be 
noted that the isolated lysosomal fractions contained 10-fold lower protein content than the cell 
lysate and that we were able to load only 3-ȝJRISURWHLQSHUeach lane. Interestingly, we 
observed lower LAMP1-signal in the lysosomal fraction in NPC1-null cells compared to CHOwt 
cells (Figure 1A). To further characterize the isolated lysosomal fractions we measured the 
activity of the lysosomal enzyme NAG (Figure 1B) and the total cholesterol levels (Figure 1C). 
We detected significantly increased activity of the NAG in the lysosomal fraction compared to 
the cell lysate both in CHOwt and in NPC1-null cells, suggesting an enrichment of lysosomes in 
the isolated fractions. In addition, a 3-fold increase of cholesterol was detected in the isolated 
lysosomal fractions from NPC1-null compared to CHOwt cells (p<0.01) (Figure 1C). This result 
is in agreement with our previous work using this model (7–9). We next performed MS-based
proteomic analysis of the isolated lysosomal fractions. We identified 1577 and 2051 proteins in 
the lysosomal fractions (found in at least two out of three replicates) of CHOwt and NPC1-null 
cells, respectively. DAVID Gene Ontology (GO) tool was used for the classification and the 
detection of the most relevant annotation terms associated with protein set of each lysosomal 
fraction in order to get the insight into their subcellular localization. GO functional annotation 
tool was used to list top terms with the minimum of 2-fold enrichment and p<0.05. In the 
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lysosomal fractions of CHOwt and NPC1-null cells the identified proteins were mainly 
represented as “membrane-bounded vesicle” and as “membrane-enclosed lumen” (Figure 1D)
Since we noticed decreased LAMP1 signal in the isolated lysosomal fraction in NPC1-null vs. 
wt cells (Figure 1A), we further investigated this. Using the same markers as in Figure 1A we
additionally analyzed all fractions collected from the isolation procedure (including flow and 
wash through fractions) by western blotting (Figure 2A). Due to the no or very low LAMP1 
signal detected in the cell lysate (Figure 1A) we loaded the same volume of each fraction and the 
input (cell lysate, which was normalized per protein amount prior the lysosomal isolation). We 
observed increased amount of LAMP1 in the flow fraction in the NPC1-null cells compared to 
CHOwt cells (a fraction containing the rest of the cell lysate which did not capture ferrofluid 
particles and thus was passed through the magnetic field). Interestingly, this feature was fully 
recovered by back expression of NPC1 protein in NPC1-null cells, suggesting that the observed 
effect is NPC1-specific (Figure 2A). Furthermore, we characterized the particle size in the 
isolated lysosomal fractions. While in the lysosomal fraction from CHOwt cells the size of the 
particles was in the narrow range with average radius of 34 nm, the particles in the lysosomal 
fraction from NPC1-null cells were in a broader size range with average radius of 135 nm
(Figure 2B). NPC1 overexpression in NPC1-null cells reverted particle size distribution and 
average radius to that as in CHOwt cells (Figure 2B).    
To further characterize lower LAMP1 signal in the isolated lysosomal fraction in NPC1-null vs. 
CHOwt cells using the “ferrofluid particles” method, we monitored the uptake, trafficking and 
degradation of dextran in these cells. For that we used fluorescein labeled dextran that had 
similar molecular weight as the one used in the ferrofluid particle suspension for lysosomal 
isolation. Firstly, we monitored its trafficking after initial 24h of intake (pulse period). At the 
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time zero (chase period), we observed no significant difference in the uptake and distribution of 
fluorescein labeled dextran between CHOwt and NPC1-null cells (Figure 3A). During several 
hours of chase we observed that small dots were accumulating to larger dots (which was 
especially visible after 6 hours of chase) in both CHOwt and NPC1-null cells, suggesting dextran 
delivery into the lysosomes. However, soon after that (at 8h and at 24h time points), in CHOwt 
cells the signal continued to accumulate in larger aggregates, while in NPC1-null cells the signal 
was noted to fade (Figure 3A). We reasoned the two possible explanations for this observation: 
1) that NPC1-null cells somehow excrete dextran in the medium and 2) that dextran leaks from 
lysosomes into the cytosol, where it is diluted and, thus, is not visible any more, which could 
also explain decreased lysosomal isolation efficiency in NPC1-null vs. wt-cells. To test these two 
possibilities we measured the levels of fluorescein signal in the cell lysate and in the medium 24 
hours after initial uptake. We did not observe significant differences of the intracellular and 
secreted fluorescein signal between the NPC1-null and CHOwt cells (Figure 3B), suggesting that 
dextran is not being secreted out of the NPC1-null cells and that it is present within the cells.
This observation indirect supports our second hypothesis of the lysosomal leakage of dextran in 
NPC1-null vs. CHOwt cells.
N-glycosylation analysis of the lysosomal glycocalyx of NPC1-null and CHOwt cells
The lysosomal glycocalyx consists of the oligosaccharides, from the lysosomal membrane 
glycoproteins (mainly LAMP1 and LAMP2), that are thought to protect the phospholipid bilayer 
with embedded proteins from the hydrolytic destruction by hydrolases in the lysosomal lumen. 
We assumed that altered glycocalyx composition may represent an additional feature of  
lysosomal (dys)function that may contribute to the potential lysosomal leakage effect thought to 
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occur in lysosomal storage diseases as well as in the most common neurodegenerative disorders, 
such as Alzheimer’s and Parkinson’s disease (34, 35). To analyse N-glycome of the lysosomal 
glycocalyx between NPC1-null and CHOwt cells from the isolated lysosomal fractions, we 
firstly separated the lysosomal membrane proteins from the lysosomal luminal proteins using 
Triton X-114 (Figure 4). N-glycomic profiles of lysosomal membrane proteins were obtained 
after PNG-ase F treatment using HILIC-UPLC analysis. The obtained chromatograms were 
separated into 37 (Figure 5) distinct chromatographic peaks. Identity of N-glycan structures 
present in each peak was elucidated by MALDI-TOF MS approach. The most abundant
structures (representing > 10% of individual peak area) present in each peak are given in Table 1 
and Figure 5. Relative abundance of the N-glycan structures was quantitatively assessed as areas 
under the peaks; the most abundant N-glycan (including isomers) among the lysosomal 
membrane proteins of both NPC1-null and CHOwt cells was a high-mannose type glycan -H9N2
(Figure 5). Even though the high-mannose glycans comprise the same amount of the lysosomal 
membrane proteins’ N-glycome (~ 38%) in NPC1-null and CHOwt cells; the statistically 
significant decrease of H9N2 and H8N2 glycans, and the increase of H7N2 and H5N2 glycans 
was detected in NPC1-null cells compared to the CHOwt. In addition, we observed the 
statistically significant increase of sialylated complex glycans (H6N5F1L1, H9N8F1L2 and 
H9N8F1L3 showed the most significant increase) in the N-glycome of lysosomal membrane 
proteins of NPC1-null vs. CHOwt cells (Table 2, Supplementary figure 1). However, the same 
aforementioned changes in the high-mannose glycans of the lysosomal membrane proteins were 
also observed in N-glycome of the whole-cell-lysate of NPC1-null vs. CHOwt cells 
(Supplementary figure 2, Supplementary table 1), indicating that the observed high-mannose N-
glycosylation alterations upon NPC1-loss of function are not specific to the lysosomal 
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glycocalyx. On the contrary, the changes of the sialylated complex glycans in the whole-cell-
lysate N-glycome compared to the changes in the lysosomal membrane proteins’ N-glycome of 
NPC1-null vs. CHOwt cells were opposite. Namely, there was a significant decrease of more 
complex and sialylated glycans and the increase of small high-mannose and neutral 
complex/hybrid glycans in the whole-cell-lysate N-glycome of NPC1-null vs. CHOwt cells 




In this work we describe changes in the lysosomal glycocalyx in a cellular model of a lysosomal 
storage disease Niemann-Pick type C (NPC). Lysosomal impairment is considered to play an 
important role in the pathogenesis of neurodegenerative diseases including the rare inherited 
lysosomal storage disorders, like Niemann-Pick type C disease (NPC), as well as the most 
common and complex Alzheimer’s and Parkinson’s disease (AD and PD). Here, we have 
characterized the N-glycan profile of the lysosomal glycocalyx of NPC1-null vs. CHOwt cells. 
Notably, in our previous studies we have substantially used this NPC disease cellular model to 
elucidate the molecular and cellular details of an AD-like phenotype in NPC (7–9, 36). Based on 
our results we speculate that changes in the N-glycome of the lysosomal membrane proteins may 
contribute to lysosomal (dys)function in NPC disease.
Lysosomes were isolated using the magnetic ferrofluid nanoparticles instead of the traditionally 
used ultracentrifugation fractionation procedures since the isolation using the magnetic beads 
reveals more pure lysosomal fractions. Indeed, our western blot analysis of endosomal and 
lysosomal marker proteins in the magnetically isolated lysosomal fractions confirmed that they 
were mainly LAMP1-positive, indicating that we have successfully isolated lysosomal 
organelles. However, we noticed that the yield of the isolated lysosomes was substantially lower 
in NPC1-null vs. CHOwt cells. This is in contrast to the recently reported lysosomal isolation 
from HeLa NPC1-KO cells using similar approach (37). In contrast to our dextran-coated 
ferrofluid nanoparticles, Tharkeshwar et al. used much smaller size coated ferrofluid 
nanoparticles which may be the reason of the different cellular behaviour of the NPC1-lacking 
lysosomes. Our further analysis of the dextran uptake and its lysosomal accumulation between 
CHOwt and NPC1-null cells revealed that leakage of lysosomes may likely explain decreased 
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lysosomal isolation efficiency in NPC1-null vs. wt-cells by the “dextran-coated ferrofluid 
nanoparticles” method. Indeed, lysosomal leakage has been proposed to occur in the most 
common neurodegenerative disorders, such as AD (38), as well as the rare LSDs, such as NPC
(39). This defect was fully recovered upon NPC1-back expression in NPC1-null cells, suggesting 
that the observed feature of decreased lysosomal isolation in the NPC1-null cells is dependent on 
NPC1-function. Moreover, particles in the isolated lysosomal fractions from NPC1-null cells 
presented with substantially increased radius (4-5 fold) and contained 3-fold more cholesterol 
than the lysosomal fraction of CHOwt cells. Altogether, these results (enlarged lysosomal 
organelles together with cholesterol accumulation) reveal that the magnetically isolated 
lysosomal fractions contain the key features of lysosomal impairment in NPC disease, indicating 
that these lysosomes could be further used for the organelle profiling.
Next, we sought to analyze the N-glycome of the lysosomal membrane proteins from the isolated 
lysosomal fractions in order to elucidate if the N-glycosylation pattern of the lysosomal 
glycocalyx is altered in NPC1-null vs. CHOwt cells and, thus, may contribute to the lysosomal 
dysfunction. Indeed, our findings support this as we observed both changes in the high-mannose 
and sialylated N-glycome patterns of the lysosomal membrane proteins between the two cell
lines. To the best of our knowledge this study is the first to report N-glycome profiling of the 
lysosomal glycocalyx. All of the detected structures have the characteristics of N-glycosylation
in CHO cell line; myriad of LacNAc structuresFRUHIXFRV\ODWLRQĮOLQNHGVLDOLFDFLGDQG
higher abundance of N-acetylneuraminic than of N- glycolylneuraminic acid (31, 32, 40).
Compared to CHO cellular glycocalyx where the main N-glycan structures were a series of core-
fucosylated asialoglycans (40), we detected that the main structures of the lysosomal N-glycome 
belong to the high-mannose glycans with H9N2 as the most abundant structure, regardless of the 
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cell line, while core-fucosylated sialylated N-glycans were the second most abundant group of 
the glycans. Although the function of the lysosomal glycocalyx remains to be elucidated, it is 
known that sialic acids can protect molecules from attack by glycosidases and proteases (34) 
which may indicate that higher level of sialylation plays a role in protecting the limiting 
lysosomal membrane from the action of degradative lysosomal enzymes in the lumen. Yet, this is 
the first study where the specific changes of N-glycosylation of the lysosomal glycocalyx were 
observed between the NPC1-null (NPC disease cellular model) and CHOwt cell lines. More 
precisely, we identified higher abundance of more complex sialylated and smaller high-mannose
N-glycans in the lysosomes derived from NPC1-null vs. wt-cells. Higher glycosylation of the 
lysosomal proteins in NPC disease was previously observed by two independent studies (41, 42).
Chen et al. suggested that only NPC2 protein is more glycosylated while others remain 
unchanged. However, Dixit et al. proved that higher level of glycosylation is not limited to NPC2 
but rather widely present in the lysosomal proteome. Indeed, in this study we detected that more 
complex and sialylated N-glycans are present in the lysosomal glycocalyx of the NPC1-null vs. 
wt-cells while the same cannot be said for the whole-cell-lysate N-glycome. Even though, the 
aforementioned changes were solely related to the lysosomal N-glycome, the changes of the 
high-mannose N-glycans were equally distributed in N-glycans of the NPC1-null cells regardless 
of their origin, i.e. cellular vs. lysosomal. It was noticed in previous studies that expression of Į-
mannosidase is higher in NPC disease which can explain higher abundance of smaller high-
mannose glycans that we observed in NPC1-null cells. This is further supported by findings 
which showed that lysosomal Į-mannosidase is capable of mannose digestion of the native 
proteins (42, 43). Moreover, higher abundance of H5N2 can be explain by lower expression of 
dolichol-phosphate-mannose (DPM) biosynthesis regulatory protein in NPC disease (44) as this 
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protein is needed to stabilize expression and localisation of DPM1, a catalytic subunit of DPM 
synthase (45). Indeed, an accumulation of H5N2 was observed in the cells with a mutation in 
DPM synthase (46). Interestingly, it has been recently reported that decreasing the lysosomal 
glycocalyx density causes cells to become less dependent on NPC1 protein function to transfer 
cholesterol across the lysosomal membrane. Namely, inhibition of O-glycosylation reduced
accumulation of cholesterol in NPC1-null cells which is the primary feature of NPC disease (20).
Since in this study we observed higher level of glycosylation in the NPC1-null vs. wt-cells this 
may indicate that glycosylation could be actively involved in cholesterol accumulation and NPC 
disease progression. 
Thus, modulation of the lysosomal glycocalyx may not only cause impairment of the lysosomal 
function but may also be used as a tool to bypass certain lysosomal defects such as cholesterol 
accumulation in NPC disease. Further glycome profiling of the lysosomal glycocalyx in other 
lysosomal storage disorders as well as the most common neurodegenerative diseases, such as AD 
and PD, is necessary to better understand the function of the lysosomal glycocalyx and to reveal 
its potential contribution in lysosomal dysfunction leading to neurodegeneration. 
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Figure 1. Characterization of the lysosomal fractions isolated using the magnetic beads from 
NPC1-null and CHOwt cells. (A) Western blot analysis of the isolated fractions: LAMP1 -
lysosomal marker, EEA1 - early endosomal marker, actin - loading control. Lysosomal fractions 
are positive for LAMP1 and are negative for EAA1 early endosomal markers; (B) N-Acetyl-ȕ-D-
glucosaminidase (NAG) activity shows a significant increase in the isolated lysosomal fractions 
vs. the cells lysate, * p<0.05; (C) cholesterol levels in the isolated lysosomal fractions from 
NPC1-null cells are significantly increased compared to CHOwt cells, ** p< 0.01; (D) GO
analysis of proteins identified in lysosomal fractions (2-fold enrichment, p< 0.05). 
Figure 2. NPC1 overexpression in NPC1-null cells reverts lysosomal isolation efficiency and the 
particle size distribution to that as in wild type cells. (A) Western blot analysis of the isolated 
fractions using the “ferrofluid particles” method: LAPM1 - lysosomal marker, EEA1 - early 
endosomal marker, actin - loading control. Upon NPC1 overexpression in NPC1-null cells 
lysosomal isolation efficiency was comparable to that as in CHOwt cells; (B) Particle size
measurement revealed broader distribution and enlarged lysosomes in NPC1-null cells compared 
to CHOwt and NPC1-transfected NPC1-null cells.
Figure 3. Decreased lysosomal isolation efficiency in NPC1-null cells vs. CHOwt is not due to 
different cellular uptake and distribution of ferrofluid dextran labeled particles, but rather is due 
to a lysosomal leakage in NPC1-null cells. (A) Cells were incubated with fluorescein labeled 
dextran for 24 hours and chased in regular medium for 0 – 24 hours. In CHOwt cells labeled 
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dextran accumulates in enlarged vesicles, i.e. lysosomes, while in NPC1-null cells signal is 
fading; (B) After 24 hours incubation with dextran (+) or without dextran (-) and 24 hours chase, 
fluorescein signal was measured in cell lysates and in the medium. There was a non-significant 
trend of cellular accumulation and decreased excretion of fluorescein labeled dextran in NPC1-
null cells compared to CHOwt cells.
Figure 4. Overlaid chromatograms of HILIC-UPLC N-glycan profiles of intraluminal, soluble 
fraction (red) and hydrophobic membrane fraction (green).
Figure 5. Representative chromatogram of 2-AB labeled N-linked glycans released from 
lysosomal membrane proteins isolated from CHOwt cells and separated by HILIC-UPLC. The 
integration areas, together with a major structure (except for GPLY16 and GPLY37 due to the 
limited evidence) presented in each glycan peak are given as shown in Table 1 and using 
glucose units as well as knowledge of the biosynthetic pathway of N-glycans in the CHO cell 
line (26, 27). Glycan peaks (glycan peaks of lysosomal glycocalyx - GPLY) are numbered from 
GPLY1-GPLY37, as used in the manuscript. Glycan peaks which percentage of area increased and 
decreased in lysosomal glycocalyx of NPC1-null cells compared to CHOwt cells (adjusted p –




Table 1. Assumed composition of N-glycome of the lysosomal membrane proteins. The 
lysosomal N-glycome was separated into 37 chromatographic peaks (glycan peaks of lysosomal 
glycocalyx - GPLY) by HILIC-UPLC and masses of individual glycan structures were detected 
by MALDI-TOF/TOF-MS. Abbreviations used are hexose (H), N-acetylhexosamine (N), fucose 
)DQGVLDOLFDFLGZLWKĮ-linkage as indicated by lactonization (NA – N-acetylneuraminic; 
NG – N-glycolylneuraminic acid).









1564.487 -0.130 335 H4N3F1 2660.404 0.389 15 H7N6F1








H3N5F1 2787.365 0.324 365 H7N6NA1





1523.653 0.061 414 H5N2F1 2933.450 0.351 1838 H7N6F1NA1




H3N6F1 GPLY25 3114.627 0.490 61 11.73 H6N5F1NA3
1767.694 -0.003 434 H4N4F1 GPLY26 3206.493 0.308 379 12.12 H7N6F1NA2








H4N5F1 3130.594 0.462 289 H6N5F1NA2NG 1





GPLY7 1929.660 -0.090 2973 7.74 H5N4F1 3206.412 0.227 98 H7N6F1NA2









H5N5F1 GPLY30 3479.530 0.261 131 13.03 H7N6F1NA3





2016.027 0.277 418 H6N3NA1 3571.660 0.343 876 H8N7F1NA2
GPLY11 2202.993 0.158 524 8.46 H5N4F1NA1 3495.576 0.312 193 H8N6NA3









1863.608 -0.083 9140 H8N2 3768.654 0.305 142 H7N6F1NA3NG 1








H5N4F1NA2 3936.708 0.259 162 H9N8F1NA2
2422.185 0.276 17 H6N5NA1 GPLY34 4117.825 0.338 72 14.33 H8N7F1NA4
37
 
GPLY17 2025.916 0.171 5989 9.65 H9N2 GPLY35 4210.126 0.481 131 14.68 H9N8F1NA3
GPLY18 2568.174 0.207 2619 9.95 H6N5F1NA1 GPLY36 4210.116 0.480 437 14.83 H9N8F1NA3










2188.100 0.302 2081 H10N2
I – Intensity, GU – Glucose unites after HILIC-UPLC analysis
† Deviation between experimental and theoretical mass using GlycoMod
 
Table 2. Differences in the lysosomal membrane proteins’ N-glycomes (glycan peaks of 
lysosomal glycocalyx - GPLY) between CHOwt and NPC1-null cells. Abbreviations used are 
hexose (H), N-acetylhexosamine (N), fucoVH)DQGVLDOLFDFLGZLWKĮ-linkage as indicated by 











GPLY1 H5N2 0.209 0.0002 0.0079 GPLY26 H7N6F1NA2 2.394 0.0889 0.1644
GPLY19 H6N5F1NA1 0.224 0.0006 0.0113 GPLY3 H5N3 0.427 0.0978 0.1723
GPLY2 H5N2 0.252 0.0025 0.0262 GPLY15 H5N4F1NA2 2.303 0.1054 0.1773
GPLY13 H8N2 3.937 0.0028 0.0262 GPLY12 H8N2 0.45 0.1238 0.1991
GPLY36 H9N8F1NA3 0.266 0.0043 0.032 GPLY23 H6N5F1NA2 0.463 0.1388 0.2139
GPLY33 H9N8F1NA2 0.276 0.0062 0.0383 GPLY22 H6N5F1NA2 1.896 0.2251 0.3332
GPLY6 H5N4 0.284 0.0081 0.0427 GPLY5 H6N2 0.55 0.2587 0.3681
GPLY29 H8N7F1NA1 3.453 0.0092 0.0427 GPLY9 H7N2 0.578 0.3029 0.4151
GPLY17 H9N2 3.372 0.0113 0.0463 GPLY35 H9N8F1NA3 0.59 0.319 0.4216
GPLY8 H7N2 0.302 0.013 0.0467 GPLY10 H6N3NA1 0.611 0.3465 0.4421
GPLY30 H7N6F1NA3 0.309 0.0151 0.0467 GPLY21 H10N2 0.712 0.526 0.6487
GPLY32 H8N7F1NA3 3.244 0.0151 0.0467 GPLY27 H7N6F1NA2 0.74 0.575 0.6863
GPLY14 H6N5F1 0.342 0.0302 0.0798 GPLY18 H6N5F1NA1 1.3 0.6486 0.7499
GPLY16 / 0.34 0.0292 0.0798 GPLY7 H5N4F1 1.234 0.698 0.7596
GPLY31 H8N7F1NA2 2.791 0.04 0.0925 GPLY25 H6N5F1NA3 1.242 0.6888 0.7596
GPLY37 H7N6F1NG 4 0.358 0.0394 0.0925 GPLY34 H8N7F1NA4 1.162 0.7944 0.8398
GPLY4 H4N4F1 0.379 0.0535 0.11 GPLY20 H10N2 0.897 0.8408 0.8642
GPLY11 H5N4F1NA1 2.651 0.0535 0.11 GPLY24 H7N6F1NA1 1.015 0.9775 0.9775
GPLY28 H7N6F1NA2 0.385 0.0586 0.114
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